These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 3981712)

  • 21. Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer.
    Ishikawa S; Soloway MS; Van der Zwaag R; Todd B
    J Urol; 1989 May; 141(5):1139-42. PubMed ID: 2651713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adverse effects during endocrine therapy for prostatic carcinoma with a high dose of estrogen.
    Shinkawa T; Ohfuji T; Osada Y; Ishisawa N
    Urol Int; 1985; 40(2):103-6. PubMed ID: 3992737
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The serum levels of testosterone and prolactin in patients with prostatic carcinoma treated with various doses of Fostrolin and bromocriptin.
    Jeromin L
    Int Urol Nephrol; 1982; 14(1):51-6. PubMed ID: 6889585
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
    J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II study of high-dose estrogens (diethylstilbestrol diphosphate) in prostate cancer.
    Citrin DL; Kies MS; Wallemark CB; Khandekar J; Kaplan E; Camacho F; Lind R
    Cancer; 1985 Aug; 56(3):457-60. PubMed ID: 4005808
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients.
    Stamey TA; Kabalin JN; Ferrari M; Yang N
    J Urol; 1989 May; 141(5):1088-90. PubMed ID: 2468797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
    St Arnaud R; Lachance R; Dupont A; Labrie F
    J Clin Endocrinol Metab; 1986 Aug; 63(2):297-302. PubMed ID: 3522618
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of hormonal therapy on plasma testosterone levels in prostatic carcinoma.
    Robinson MR; Thomas BS
    Br Med J; 1971 Nov; 4(5784):391-4. PubMed ID: 5124437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pre-treatment testosterone levels: significance in androgen deprivation therapy.
    Hickey D; Todd B; Soloway MS
    J Urol; 1986 Nov; 136(5):1038-40. PubMed ID: 3095566
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer.
    Arai Y; Yoshiki T; Yoshida O
    J Urol; 1990 Dec; 144(6):1415-9. PubMed ID: 1700155
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Orchiectomy for advanced prostatic carcinoma. A reevaluation.
    Blackard CE; Byar DP; Jordan WP
    Urology; 1973 Jun; 1(6):553-60. PubMed ID: 4588820
    [No Abstract]   [Full Text] [Related]  

  • 33. Early combined hormonal and chemotherapy for metastatic carcinoma of prostate.
    Mukamel E; Nissenkorn I; Servadio C
    Urology; 1980 Sep; 16(3):257-60. PubMed ID: 7423702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endocrine treatment of prostatic cancer.
    Pollen JJ
    Urology; 1983 Jun; 21(6):555-8. PubMed ID: 6868224
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Decrease in anticoagulant factors in patients with prostate cancer treated with diethylstilbestrol diphosphate].
    Hayashi N; Wada T; Ikemoto I; Oishi Y; Suzuki H; Ueda M
    Nihon Hinyokika Gakkai Zasshi; 2003 Mar; 94(3):420-7. PubMed ID: 12710076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Castration in the treatment of locally advanced or metastatic prostate cancer].
    Mongiat-Artus P
    Rev Prat; 2013 Apr; 63(4):509-10. PubMed ID: 23682480
    [No Abstract]   [Full Text] [Related]  

  • 37. Endocrine effects of oestrogen treatment in patients with prostatic cancer.
    Schnorr D; Mebel M; Dörner G; Stahl F; Rohde W
    Eur Urol; 1976; 2(2):85-8. PubMed ID: 971678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of orchiectomy and various doses of stilbestrol on plasma testosterone levels in patients with carcinoma of the prostate.
    Mackler MA; Liberti JP; Smith MJ; Prout GR
    Surg Forum; 1970; 21():540-1. PubMed ID: 5535268
    [No Abstract]   [Full Text] [Related]  

  • 39. Hormonal therapy: the benefits of postponed initiation.
    Cockburn AG
    Urology; 1984 Nov; 24(5 Suppl):24-6. PubMed ID: 6388093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
    Appu S; Lawrentschuk N; Grills RJ; Neerhut G
    J Urol; 2005 Jul; 174(1):140-2. PubMed ID: 15947599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.